Xeligekimab

Xeligekimab
Monoclonal antibody
Type	?
Clinical data
Other names	GR1501
Legal status
Legal status	Investigational;
Identifiers
CAS Number	2382921-73-3;
UNII	MC5WXU879E;

Xeligekimab (GR1501) is a monoclonal antibody that neutralizes interleukin-17A;^[1] it is being developed for plaque psoriasis,^[2] axial spondyloarthritis,^[3] and lupus nephritis.^[4] It is in a Phase III trial in 2023.^[5]

References[edit]

^ Shan, Yunlong; Shi, Ke; Qian, Xuelong; Chang, Zhiyuan; Yang, Jiaqian; Gao, Yuan; Jin, Wei; Luo, Qiong; Xu, Qiang (17 September 2019). "Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A". Biochemical and Biophysical Research Communications. 517 (2): 303–309. doi:10.1016/j.bbrc.2019.07.078. ISSN 1090-2104. PMID 31353088. S2CID 198964908.
^ Dong, Wenliang; Nie, Xiaoyan; Wang, Jiaxue; Xia, Lin; Cai, Lin; Wang, Qian; Wang, Wei; Fu, Weixing; Wang, Qi; Shen, Tiantian; Fan, Huaying; Niu, Suping; Cui, Yimin; Zheng, Qingshan; Zhang, Jianzhong; Fang, Yi (1 November 2020). "Randomised, double-blind, multicentre, phase I/II dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol". BMJ Open. 10 (11): e039067. doi:10.1136/bmjopen-2020-039067. ISSN 2044-6055. PMC 7689088. PMID 33234634.
^ Sen, Rouhin; Caplan, Liron (1 December 2022). "Current treatment and molecular targets for axial spondyloarthritis: Evidence from randomized controlled trials". Current Opinion in Pharmacology. 67: 102307. doi:10.1016/j.coph.2022.102307. ISSN 1471-4892. PMID 36335714. S2CID 253331181.
^ "Delving into the Latest Updates on Xeligekimab with Synapse". synapse.patsnap.com. Retrieved 4 November 2023.
^ Denis, Agathe; Sztejkowski, Cédric; Arnaud, Laurent; Becker, Guillaume; Felten, Renaud (2023). "The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials". RMD Open. 9 (3): e003279. doi:10.1136/rmdopen-2023-003279. ISSN 2056-5933. PMC 10387652. PMID 37507210.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Shan, Yunlong; Shi, Ke; Qian, Xuelong; Chang, Zhiyuan; Yang, Jiaqian; Gao, Yuan; Jin, Wei; Luo, Qiong; Xu, Qiang (17 September 2019). "Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A". Biochemical and Biophysical Research Communications. 517 (2): 303–309. doi:10.1016/j.bbrc.2019.07.078. ISSN 1090-2104. PMID 31353088. S2CID 198964908.

[2] Dong, Wenliang; Nie, Xiaoyan; Wang, Jiaxue; Xia, Lin; Cai, Lin; Wang, Qian; Wang, Wei; Fu, Weixing; Wang, Qi; Shen, Tiantian; Fan, Huaying; Niu, Suping; Cui, Yimin; Zheng, Qingshan; Zhang, Jianzhong; Fang, Yi (1 November 2020). "Randomised, double-blind, multicentre, phase I/II dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol". BMJ Open. 10 (11): e039067. doi:10.1136/bmjopen-2020-039067. ISSN 2044-6055. PMC 7689088. PMID 33234634.

[3] Sen, Rouhin; Caplan, Liron (1 December 2022). "Current treatment and molecular targets for axial spondyloarthritis: Evidence from randomized controlled trials". Current Opinion in Pharmacology. 67: 102307. doi:10.1016/j.coph.2022.102307. ISSN 1471-4892. PMID 36335714. S2CID 253331181.

[4] "Delving into the Latest Updates on Xeligekimab with Synapse". synapse.patsnap.com. Retrieved 4 November 2023.

[5] Denis, Agathe; Sztejkowski, Cédric; Arnaud, Laurent; Becker, Guillaume; Felten, Renaud (2023). "The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials". RMD Open. 9 (3): e003279. doi:10.1136/rmdopen-2023-003279. ISSN 2056-5933. PMC 10387652. PMID 37507210.

[1]

[2]

[3]

[4]

[5]